Cetaphil Redness Relieving Daily Facial Moisturizer With Sunscreen Spf 40 Cream
NDC Package 0299-4138-00
Package Information
Cetaphil Redness Relieving Daily Facial Moisturizer With Sunscreen Spf 40 (titanium dioxide, zinc oxide) cream is • Apply liberally 15 minutes before sun exposure.• Use a water resistant sunscreen if swimming or sweating• Reapply at least every 2 hours.• Children under 6 months: ask a doctorSUN PROTECTION MEASURES: Spending time in the sun increases your risk of cancer and early skin aging. This formulation utilizes a cream delivery system. Marketed by Galderma Laboratories, L.p., this product is identified by NDC 0299-4138 and is authorized under FDA application M020.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0299 - Galderma Laboratories, L.p.
- 0299-4138 - Cetaphil Redness Relieving Daily Facial Moisturizer With Sunscreen Spf 40
- 0299-4138-00 - 1 TUBE in 1 CARTON / 50 mL in 1 TUBE
- 0299-4138 - Cetaphil Redness Relieving Daily Facial Moisturizer With Sunscreen Spf 40
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0299-4138). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0299-4138-00 identifies a specific commercial package of 1 tube in 1 carton / 50 ml in 1 tube of Cetaphil Redness Relieving Daily Facial Moisturizer With Sunscreen Spf 40, a human over the counter drug labeled by Galderma Laboratories, L.p.. This cream is formulated for topical use and contains titanium dioxide; zinc oxide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Galderma Laboratories, L.p. on July 20, 2023. The current certification is valid through December 31, 2026.
How is this Galderma Laboratories, L.p. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00299413800. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.